home / stock / soly / soly news

SOLY News and Press, Soliton Inc. From 08/14/19

Stock Information
Company Name: Soliton Inc.
Stock Symbol: SOLY
Market: NYSE
Website: soliton.com
Menu
SOLY SOLY Quote SOLY Short SOLY News SOLY Articles SOLY Message Board
Get SOLY Alerts

News, Short Squeeze, Breakout and More Instantly...
SOLY - Non-Invasive Cellulite Treatments and Devices Dominating Billion Dollar Market

August 14, 2019 Palm Beach, FL – August 14, 2019 – People with cellulite are not as happy as those without cellulite. That may seem to be self-evident, but now it is supported by studies. One such report, a study published by Surgical and Cosmetic Dermatology, fo...
SOLY - Soliton Treats First Patients in Pivotal Cellulite Trial

HOUSTON , Aug. 14, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today anno...

SOLY - CEPU, CGAL, LOMA and PAM among midday movers

Gainers : Arcadia Biosciences (NASDAQ: RKDA ) +49% . Soliton (NASDAQ: SOLY ) +24% . GTT Communications (NYSE: GTT ) +17% . Everspin Technologies (NASDAQ: MRAM ) +16% . AMAG Pharmaceuticals (NASDAQ: AMAG ) +15% . China SXT Pharmaceuticals (NASDAQ: SXTC ) +15% . TrueCar (NASDAQ: T...

SOLY - Cellulite Treatment Market Projected To Reach $1,438.5 Billion By 2026

August 12, 2019 Palm Beach, FL – August 12, 2019 – Cellulite has been the bane of many women (and men too) for years, but the market is expected to rise significantly through 2026, industry reports project. One report said that the global cellulite treatment market...
SOLY - Soliton Announces Patient Recruitment Has Begun for Pivotal Cellulite Trial

HOUSTON , Aug. 12, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today anno...

SOLY - Soliton Completes Site Enrollment and Conducts Initial Site Training to Start Pivotal Cellulite Trial

HOUSTON , Aug. 6, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced ...

SOLY - Soliton Partners with Clear Dermatology and Aesthetics Center to Advance Pivotal Cellulite Trial

HOUSTON , Aug. 5, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today annou...
SOLY - Soliton Announces IRB Approval

HOUSTON , July 29, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today anno...

SOLY - Soliton Enlists Chicago Cosmetic Surgery and Dermatology to Advance Pivotal Cellulite Trial

HOUSTON , July 25, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced...

SOLY - Soliton's FDA Cleared Device is Granted Key Patent

HOUSTON , July 23, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today anno...
Previous 10 Next 10